CGON — CG Oncology Cashflow Statement
0.000.00%
Last trade - 00:00- $5.46bn
- $4.72bn
- $4.04m
Annual cashflow statement for CG Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -12.8 | -35.4 | -48.6 | -88 | -161 |
| Depreciation | |||||
| Non-Cash Items | 1.14 | 1.19 | -0.528 | 6.39 | 24.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.97 | 4.44 | 3.44 | 2.91 | 2.28 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -13.7 | -29.8 | -45.7 | -78.7 | -132 |
| Capital Expenditures | -0.097 | -0.014 | — | -0.234 | -0.134 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -55.3 | -121 | -301 | -246 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.097 | -55.4 | -121 | -301 | -246 |
| Financing Cash Flow Items | — | — | -3.42 | -3.42 | -0.316 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 15.4 | 120 | 87 | 628 | 154 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1.7 | 34.5 | -79.9 | 249 | -225 |